Clearwater advises the management team at Rosemont Pharmaceuticals on its MBO with Inflexion

Transaction

Inflexion acquired Rosemont Pharmaceuticals from Perrigo

Management Advisory

Undisclosed

Role

Adviser to the management team of Rosemont Pharmaceuticals in respect of its acquisition by Inflexion from Perrigo

Sector

Healthcare

Region

United Kingdom

Clearwater has advised the management team at Rosemont Pharmaceuticals (Rosemont), the UK’s leading liquid pharmaceuticals business, on its carve out from US listed company Perrigo, to Inflexion.

Rosemont’s portfolio of over 130 oral liquid medicines includes over 70 licensed products which are sold into the UK as well as the US, Continental Europe and the Middle East. The business benefits from strong R&D and innovation, and has built a track record of successful new product launches.

With substantial experience in successfully executing carve-outs, Inflexion will draw upon its healthcare expertise to establish Rosemont as a standalone business and invest further in innovation and new product development. Inflexion will also support the geographical expansion of the business.

We’re extremely pleased to be able to announce this exciting new chapter for Rosemont. As a very well established and respected supplier in the industry, we look forward to working with Inflexion and drawing on their relevant experience in our sector to continue to invest in the business and expand our quality product range.
Howard Taylor, CEO, Rosemont

We are delighted to be partnering with Rosemont on their journey to become a standalone business. Our experience in helping businesses to become independent combined with our success in growing healthcare businesses make us confident our partnership will be an excellent foundation for further innovation and new product development.
Simon Turner, Managing Partner, Inflexion

It was a pleasure to work with Howard and the team on assisting them with their transition to private equity ownership. As leaders in their respective markets, we would like to wish the team all the best and a successful partnership that will increase their already strong reputation.
Richard Goldsack, Partner, Clearwater

Advisers

Richard Goldsack

Managing Director 0333 034 9125 richard.goldsack@clearwatercf.com Connect

Mark Gillingham

Director +44 845 052 0368 mark.gillingham@clearwatercf.com Connect

Transactions

Creating a stronger future for fertility care

Adviser to Manchester Fertility Group on its sale to Amulet Capital Partners-backed TFP Fertility Group

group healthcare workers businessman using laptop

Ireland's leading occupational healthcare provider secures strategic investment from mid-market private equity

Adviser to Medmark on its investment from Phoenix Equity Partners

Refinancing enhances capacity for growth in health and life sciences advisory market

Adviser to Baird Capital-backed Newmarket Strategy

pharmaceutical bottling process modern industrial production

Landmark investment in UK life sciences market access technology and consultancy

Adviser to Access Infinity on its investment from CBPE Capital

View all